This report on hematopoietic stem cells transplantation market studies various transplant types and applications. Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The indications for HSCT thus are wide; the most frequent indication as per reported by Worldwide Network for Blood and Marrow Transplantation Group (WNBT) (2013) is lymphoproliferative disorder (53.2% of all HSCT), 12% of whom received allogeneic and the rest received autologous transplant. Plasma cell disorders are the most frequent indication in this group. A multitude of literature published by researchers and organizations demonstrate that autologous transplant own a greater edge against allogeneic HSCT.

For the purpose of this study, the global hematopoietic stem cells transplantation market on the basis of transplant type is segmented into allogeneic transplant, and autologous transplant. Market size estimates and forecast for these segments for the period 2013 to 2023 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2023, considering 2015 as the base year.

On the basis of application type global hematopoietic stem cells transplantation market is segmented as leukemia, lymphoproliferative disorders, solid tumors, and non-malignant disorders. Market size estimates and forecast for these segments for the period 2013 to 2023 are provided in terms of USD Mn along with the respective compounded annual growth rates (CAGRs) for the period 2016 to 2023, considering 2015 as the base year.

The hematopoietic stem cells transplantation market has been geographically categorized into major regions such as North America, Europe, Asia Pacific, Latin America, Middle East and Africa. Each geography market is further split to provide market revenue for select countries such as the U.S., Canada, U.K. Germany, China, Japan, Brazil, and GCC countries. Market size and forecast for these segments during 2013 to 2023 and their CAGRs for the period 2016 to 2023 are provided in this report.

The major key players profiled in the hematopoietic stem cells transplantation market are on the basis of various characteristics such as business description, financial health and budget allocation, product portfolio, and news coverage. The key players profiled in this report are Kite Pharma Inc., Thermo Fisher Scientific, PromoCell, CellGenix Technologie Transfer GmbH, Cesca Therapeutics Inc.,  R&D Systems, Genlantis, Lonza Group Ltd., TiGenix N.V., and ScienCell Research Laboratories.

Hematopoietic stem cell transplantation is defined as intravenous infusion of hematopoietic stem and progenitor cells for the purpose of establishing immune and marrow functions in patients with variety of inherited and acquired malignancies and non-malignancies. Hematologic malignancies such as leukemia, lymphoma and myeloma and non-malignant conditions such as bone marrow disorders (aplastic anemia) and genetic diseases concerned with abnormal hematopoiesis and function such as sickle cell anemia, thalassemia, and combined immunodeficiency. In 2015, lymphoproliferative disorders and leukemia accounted for more than 50% of the market share. According to cancer research UK, leukemia is the 11th most common cancer worldwide which represented 2% of total cancer cases. Its incidence rates are the highest in Australia and New Zealand and the least in West Africa. In 2016, 60,140 individuals are expected to be diagnosed with leukemia and an estimated 345,422 people were living with leukemia in the U.S. As the prevalence of leukemia is anticipated to continue to grow, it is expected that that demand for more effective treatment options will further augment. The major conditions in lymphoproliferative disorders that use HSCT as a viable treatment option are plasma cell disorders, Hodgkin’s disease, non-Hodgkin lymphoma, and other lymphomas. HSCT is frequently considered for treating patients with non-Hodgkin lymphoma (NHL). Autologous transplant is preferred for patients with relapsed non-Hodgkin lymphoma or the patients in first remission. NHL patients are recommended allogeneic HSCT due to the high rate of relapse observed after chemotherapy and autologous HSCT. Allogeneic HSCT in indolent lymphoproliferative disorders allow graft versus leukemia effect and thus the risk of graft contamination by residual tumor cells is kept at bay.

Hematopoietic stem cell transplants (HSCT) present to a valid treatment for several congenital and other hematopoietic system disorders, post chemotherapy, and immune sensitive diseases. HSCT is also preferred for replacement of cellular components and deficient cells. The scope of HSCT procedure is anticipated to expand through the future decades. The list of indications for both allogeneic and autologous HSCT of both malignant and non-malignant blood disorders will continue to grow. Other life-threatening conditions such as metabolic diseases, autoimmune conditions, and genetic diseases will be further scrutinized for HSCT treatment. The last few decades have fetched improvement in the survival rates of the patients diagnosed with conditions such as multiple myeloma. Several factors such as better supportive care, access to hematopoietic progenitor cell transplant and availability of breakthrough drugs contribute to the longevity of patients suffering from malignant and non-malignant blood disorders. Autologous HSCT has been preferred over allogeneic HSCT due to absence of risk of graft versus host disease.

In base year 2015, North America was observed as the largest and most potential regional market for hematopoietic stem cells transplantation. North America constitutes regional markets of U.S. and Canada, the rising prevalence of cancers and anemia is the major driver for the growth of global hematopoietic stem cell transplant market. The developed healthcare infrastructure, high public awareness related to stem cell transplant, and rising prevalence awareness related to cancer and rare diseases are the key factors assisting the growth of North America hematopoietic stem cell transplantation market. Asia Pacific is the expected to be the most potential regional market for hematopoietic stem cell transplants market by 2023. Over the next six years, the growth of the market in the Asia-Pacific region is likely to be centered in Japan, South Korea, China, and India. Numerous factors such as developing economical landscape and industrialization, increasing disposable incomes, growing public awareness related to stem cell therapy, and increasing government support through providing favorable environments for stem cell research laboratories are the major factors expected to assist the growth of Asia Pacific market.

Historical & Forecast Period

This study report represents analysis of each segment from 2022 to 2032 considering 2023 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2024 to 2032.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Hematopoietic Stem Cells Transplantation market are as follows:

• Research and development budgets of manufacturers and government spending
• Revenues of key companies in the market segment
• Number of end users and consumption volume, price and value.
• Geographical revenues generate by countries considered in the report
• Micro and macro environment factors that are currently influencing the Hematopoietic Stem Cells Transplantation market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Key questions answered in this report

• What are the key micro and macro environmental factors that are impacting the growth of Hematopoietic Stem Cells Transplantation market?
• What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?
• Estimated forecast and market projections up to 2032.
• Which segment accounts for the fastest CAGR during the forecast period?
• Which market segment holds a larger market share and why?
• Are low and middle-income economies investing in the Hematopoietic Stem Cells Transplantation market?
• Which is the largest regional market for Hematopoietic Stem Cells Transplantation market?
• What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?
• Which are the key trends driving Hematopoietic Stem Cells Transplantation market growth?
• Who are the key competitors and what are their key strategies to enhance their market presence in the Hematopoietic Stem Cells Transplantation market worldwide?